Bozen, Sud-Tirol, Italy – January 21st, 2013.
Health Robotics reported today that it conducted a retrospective review of records for all “live” patient doses at its global Oncology Robot customers as of December 4, 2012, right after Intelligent Hospital Systems announced that their RIVA medical device had produced that same day its “first-ever chemotherapy patient dose”.
Gaspar DeViedma, Health Robotics’ Executive Vice President and Board Member, stated: “As of December 4, 2012, and not including the old generation robots with patents licensed to Loccioni [APOTECAchemo]
Health-System Pharmacists are still questioning why it took so long for RIVA to make its first-ever chemotherapy dose at Princess Margaret Cancer Centre [Toronto], especially given the fact that IHS’ precursor (Technology 2000) announced the chemotherapy robot as far back as a 1989 ASHP Journal article . Moreover, IHS issued many chemotherapy installation news  releases at University of California San Francisco (12/2006, and same hospital again in 12/2009), Fresenius Kabi (02/2009), Royal Victoria in Barrie, Canada (01/2010), and Baxter Australia (02/2010). What really happened to all these other RIVA chemotherapy installations that had been waiting for many years before Princess Margaret? Why St. Boniface Hospital in Winnipeg has yet to implement its own 1989 invention after all these years? Should hospitals really expect 5+ years RIVA installation cycles?
Mr. DeViedma concluded: “The crude reality is that RIVA has repeatedly failed multiple inspections by TGA (Australian equivalent of the FDA) at all 4 Australian RIVA Robot installations announced in 2009 and 2010, with RIVA still not been cleared for “live patient doses” by the TGA, until a myriad of safety modifications mandated by TGA’s inspectors are made to RIVA for chemotherapy use. Equally, only deafening silence comes out of the rest of installations in America, which were supposed to have produced results many years ago. These are important matters for any Health-System, so they can be able to fact-check the hype and the fiction.”
About Health Robotics:
Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 300 hospital installations in 5 continents with the only fully-integrated robotics-based technology, IV Workflow, and manual compounding software automation solution. Health Robotics’ second generation solutions [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies [4,5] to greatly contribute to ease hospitals’ growing pressures to improve patient safety , increase throughput, and contain costs . Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics’ medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug  and diluent  exchange errors, improve drug potency , decrease other medical mistakes and sterility risks, work more efficiently , reduce waste and controlled substances’ diversion, and diminish the gap between rising patient volume/acuity, and scarce nursing and pharmacy staff. For more information, please visit: http://www.health-
For additional information, please contact:
1. Asparaginase. Azacitidine, Bendamustin, Bevacizumab, Bleomycin, Bortezomib, Busulfan, Carboplatin, Cetuximab, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Gemtuzumab, Ibrituximab, Idarubicin, Ifosfamide, Infliximab, Irinotecan, Ixabepilone, Liposomal Doxorubicin, Melphalan , Mesna, Methotrexate, Mitomycin, Mitoxantrone, Mitumomab, Nelarabine, Nimustine, Ofatumumab, Oxaliplatin
2. Am J Hosp Pharm 46(11): 2286-‐93 1989. St. Boniface Hospital, Winnipeg.
4. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women’s Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
5. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.